Peakdale and Cyprotex collaborate on drug-like screening compounds

04-Aug-2004

Peakdale Molecular and Cyprotex have announced their collaboration in the application of ADME technology to maximise the drug-like properties of Peakdale's unique screening compounds.

Peakdale has used its innovative chemistry expertise to develop and synthesise up to 8,500 novel, lead-like molecules that complement the chemical space of other compound collections. In the agreement, Cyprotex will use its Cloe Screen(TM) high throughput screening technology to evaluate the absorption, distribution, metabolism and excretion (ADME) properties of these compounds. The companies will use the ADME data to develop predictive models that will be used to enhance the design of further novel compounds yet to be synthesised.

The collaboration has been driven by Pharmaceutical and Biotechnology companies needs for improved productivity within their drug discovery activities. By providing compounds with enhanced ADME profiles Peakdale can offer its clients superior starting points from which to discover potential new drugs, as well as making significant time-savings in subsequent optimisation.

Commenting on the collaboration, Dr. Gareth Jenkins, Peakdale's Business Development Manager said, "We are delighted to enter into this collaboration which will enable Peakdale to offer screening compounds that are more drug-like and better characterised. Our customers already benefit from our novel chemistry expertise. Now they can benefit further from better quality compounds, faster development times and reduced risk from failure in clinical trials."

Cyprotex Chief Scientific Officer David Leahy added, "Consistent, high quality compound data is essential for efficient drug discovery because it enables you to predict the potential of new compounds before they've even been synthesised. In order to develop better drugs faster, the industry needs to start with compounds that have the best potential to succeed as drugs. Combining our predictive models with Peakdale's unique chemistry will offer drug-like leads that will be ready for trials earlier and offer a greater chance of success."

https://www.bionity.com/en/news/38921/peakdale-and-cyprotex-collaborate-on-drug-like-screening-compounds.html